Nisa Investment Advisors LLC boosted its stake in shares of Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) by 5,137.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,900 shares of the company’s stock after acquiring an additional 41,100 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Rubius Therapeutics were worth $231,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. Byrne Asset Management LLC bought a new stake in Rubius Therapeutics during the fourth quarter worth approximately $37,000. Capital World Investors increased its stake in Rubius Therapeutics by 3.8% during the fourth quarter. Capital World Investors now owns 2,751,000 shares of the company’s stock worth $26,630,000 after acquiring an additional 100,000 shares during the last quarter. Lombard Odier Asset Management Switzerland SA increased its stake in Rubius Therapeutics by 9.2% during the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 267,653 shares of the company’s stock worth $2,591,000 after acquiring an additional 22,640 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in Rubius Therapeutics by 70.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 12,773 shares of the company’s stock worth $124,000 after acquiring an additional 5,295 shares during the last quarter. Finally, ARCH Venture Management LLC bought a new stake in Rubius Therapeutics during the fourth quarter worth approximately $3,387,000. 98.93% of the stock is owned by institutional investors.
Rubius Therapeutics Stock Up 4.3 %
Shares of NASDAQ:RUBY opened at $0.73 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market capitalization of $65.86 million, a PE ratio of -0.32 and a beta of 2.82. The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $3.39. Rubius Therapeutics, Inc. has a 1 year low of $0.70 and a 1 year high of $24.84.
Wall Street Analyst Weigh In
Several brokerages have weighed in on RUBY. HC Wainwright reduced their price objective on Rubius Therapeutics from $15.00 to $8.00 in a research note on Wednesday, May 11th. Guggenheim dropped their target price on Rubius Therapeutics from $25.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, April 11th. Morgan Stanley dropped their target price on Rubius Therapeutics from $15.00 to $4.00 and set an “equal weight” rating for the company in a research report on Monday, April 11th. Finally, SVB Leerink dropped their target price on Rubius Therapeutics from $5.00 to $3.00 and set a “market perform” rating for the company in a research report on Monday, April 11th.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
- Get a free copy of the StockNews.com research report on Rubius Therapeutics (RUBY)
- Can These Two Airline Stocks Overcome Gravity And Fly Higher?
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
- Consumer Staple Kraft-Heinz Quietly Builds Momentum
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.